05:27 AM EDT, 10/27/2026 (MT Newswires) -- GSK (GSK.L) expects to nearly double its existing clinical-stage cancer drug portfolio of 15 assets in 2027, following a series of acquisitions and licensing deals, The Wall Street Journal reported Tuesday. In an interview with the news agency, GSK Senior Vice President and Global Head of Oncology, Research & Development Hesham Abdullah said the British drugmaker is fast-tracking its return to oncology, with five currently approved cancer treatments and a potential sixth therapy nearing approval in a few weeks. GSK could also have 19 to 20 late-stage cancer studies in 2027, Abdullah added.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.